RxDoctor Payments Data

Amy Laitinen, MD

Neurology · Boca Raton, FLNPI 1255863148

Payments from drug & device makers

$83,436in general payments, 2019–2025

Across 267 payments — averaging $312.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TG Therapeutics, Inc.$35K
  • Novartis$22K
  • Genentech USA, Inc.$11K
  • Amgen$5K
  • EMD Serono, Inc.$4K
  • Sanofi$4K
  • plus $2K from 13 others
$19in research payments, 2019–2025

Across 1 payment — averaging $18.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis Pharma AG$19

What the payments were for

  • Consulting fees$19,21152%
  • Speaking & faculty fees$2,7007%
  • Travel & lodging$3,2279%
  • Food & beverage$11,55331%
  • Education$1931%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,436 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$75,827
Medicare patients
212
Services billed
1,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab84$711,350
Emgality PenGalcanezumab-Gnlm45$37,982
Dalfampridine ErDalfampridine44$17,013
Nurtec OdtRimegepant Sulfate12$14,924
UbrelvyUbrogepant11$8,767
Baclofen64$2,107
Teriflunomide11$1,178
Modafinil30$761
Gabapentin43$603
Naratriptan Hcl23$579
Dimethyl Fumarate11$521
RizatriptanRizatriptan Benzoate25$441
Bupropion XlBupropion Hcl12$433
Duloxetine Hcl18$358
Tizanidine Hcl17$268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$52$14,92412 claims
AbbVieUbrelvy$236$8,76711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →